LLS Issues Statement Regarding the FDA and Iclusig

The Leukemia & Lymphoma Society (LLS) has issued a statement on the FDA's call for Ariad Pharmaceuticals to suspend marketing and sales of its therapy for chronic myeloid leukemia (CML), Iclusig (ponatinib).

As reported yesterday, the FDA is investigating serious health risks associated with Iclusig and consequently issued recommendations to patients either on the drug or with CML.

Discussing medical risks

In accord with those recommendations, the LLS is encouraging all patients currently receiving Iclusig to discuss the risks and benefits of continuing to take the drug with their doctor. Patients responding to the drug and who have no other alternatives can obtain it on a compassionate use basis, but need to speak with their oncologists immediately.

The LLS has an information resource center available for patients to call Monday through Friday from 9 a.m. to 6 p.m. ET at 1-800-955-4572 for questions and concerns.

Mark Velleca, M.D., Ph.D., chief policy and advocacy officer for LLS, added:

The Leukemia & Lymphoma Society exists to find cures and ensure access to treatments for blood cancer patients. As such, we felt it was important to comment on this important access issue. Working with CML physicians and other advocacy groups, we have requested that FDA facilitate continued access to ponatinib for certain patients – such as those in blast crisis – for whom interruption of therapy could be extremely detrimental.

Source: LLS

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap